相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of cabergoline monotherapy in Cushing' disease: an individual participant data meta-analysis (vol 41, pg 1445, 2018)
R. Palui et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2022)
Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study
Andre Lacroix et al.
PITUITARY (2020)
Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study
A. Lacroix et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Pasireotide for acromegaly: long- term outcomes from an extension to the Phase III PAOLA study
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas
Jose Miguel Hinojosa-Amaya et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
Rosario Pivonello et al.
FRONTIERS IN ENDOCRINOLOGY (2020)
Management of patients with persistent or recurrent Cushing's disease after initial pituitary surgery
Cristina Capatina et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2020)
Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
Maria Fleseriu et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study
Maria Fleseriu et al.
CLINICAL ENDOCRINOLOGY (2019)
Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis
R. Palui et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2018)
Dopamine Agonists and Impulse Control Disorders: A Complex Association
Marie Grall-Bronnec et al.
DRUG SAFETY (2018)
Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
S. Petersenn et al.
ENDOCRINE (2017)
PITUITARY GLAND Mortality in Cushing disease
John Newell-Price
NATURE REVIEWS ENDOCRINOLOGY (2016)
The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center
Chiara Simeoli et al.
ENDOCRINE (2015)
Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?
M. Barbot et al.
PITUITARY (2014)
Cabergoline treatment in acromegaly: pros
Monica Marazuela et al.
ENDOCRINE (2014)
Glucocorticoids and the regulation of growth hormone secretion
Gherardo Mazziotti et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease
Annamaria Colao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mitotane, Metyrapone, and Ketoconazole Combination Therapy as an Alternative to Rescue Adrenalectomy for Severe ACTH-Dependent Cushing's Syndrome
Peter Kamenicky et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report
Marcos Paulo Manavela et al.
Pituitary (2011)
Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease
Richard A. Feelders et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease
Lucio Vilar et al.
PITUITARY (2010)
Treatment of Pituitary-Dependent Cushing's Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial
M. Boscaro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
The Medical Treatment of Cushing's Disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery
Rosario Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Pasireotide (SOM230): Development, mechanism of action and potential applications
Herbert A. Schmid
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 - Co-immunoprecipitation and fluorescence resonance energy transfer analysis
Alessandra Baragli et al.
CELLULAR SIGNALLING (2007)
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
M Rocheville et al.
SCIENCE (2000)
分享论文
